Efflux Pump Inhibiting Properties of Racemic Phenothiazine Derivatives and their  Enantiomers on the Bacterial AcrAB-TolC System by Spengler, Gabriella et al.
Abstract. Background/Aim: Bacterial resistance to
antibiotics has become a serious problem in antibacterial
chemotherapy and resistance of bacteria to chemically-
unrelated anti-microbial agents can be associated with the
over-expression of efflux pumps. The simultaneous therapy
with efflux pump inhibitors (EPIs) could be a solution to
improve the effectiveness of antibiotics. The response of an
organism to an EPI often depends on how that molecule fits
a particular site of a protein. Because enantiomers of a given
compound rotate plane-polarized light in a solution by the
same angle but in opposite directions, the rational drug
design should take the chirality into account if there is a
difference between the racemic compound and its
enantiomers. Materials and Methods: The main goal of the
present study was to elucidate the role of chirality of N-
hydroxyalkyl-2-aminophenothiazines as effective EPIs by an
automated method that uses the general efflux pump
substrate ethidium bromide (EB) for the assessment of
AcrAB-TolC system of wild-type Escherichia coli K-12
AG100. It has been shown that the most active EPIs among
the N-hydroxyalkyl-2-aminophenothiazines were the
compounds rac-3i, (+)-3i, and (–)-3i by modulating the
AcrAB-TolC efflux pump. Conclusion: Comparison of effects
of enantiomeric pairs revealed that their activities were
similar to that of racemic derivatives. Moreover, there was
no significant difference between the racemic compounds
and their enantiomers related to their antibacterial and
efflux pump inhibiting effects.
Drug resistance has evidently appeared in response to
selective pressures resulting from the excessive use of
antibiotics and other anti-microbials. Multidrug efﬂux
systems are responsible for clinically important resistance to
chemotherapeutic agents in pathogenic bacteria, fungi,
parasites and in human cancer cells. Efflux mechanisms of
bacteria, namely pumping of anti-microbial agents out of the
cells play an important role in anti-microbial resistance of
pathogenic bacteria. Bacterial anti-microbial efflux systems
can be divided into five superfamily classes, the major
facilitator (MF) superfamily, the ATP-binding cassette (ABC)
superfamily, the resistance-nodulation-division (RND)
superfamily, the small multidrug resistance (SMR)
superfamily and the multidrug and toxic compound extrusion
(MATE) superfamily (1, 2).
The use of efflux pump inhibitors (EPIs) has been
investigated in order to improve the activity of antibiotics
and the goal of the pharmacological chemistry has been the
development of compounds that decrease the level of
intrinsic resistance, significantly reverse acquired resistance
and promote the decrease of emergence of multidrug
resistant bacteria (3). Considering the main objective of
using EPIs, these compounds should increase the
susceptibility of bacteria to one or more antibiotics. The EPIs
can address various efflux targets among which the
followings can be emphasized: (i) expression of genes that
induces multidrug resistance (MDR), (ii) assembly of
membrane transporter complex responsible for drug efflux,
(iii) energy involved in the activity of transporter proteins
and (iv) inhibition of the movement of molecules inside the
efflux channel by competition or blocking (4).
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The rational drug design should consider the chirality of
the molecules if there is a difference between the racemic
compound and its enantiomers. In addition, it has been found
that the S-enantiomer and R-enantiomer of thioridazine did
not differentially affect the growth of Mycobacterium
tuberculosis strains (5). 
The role of chirality of EPIs was investigated in case of
the enantiomers of tricyclic compounds, such as
methotrimeprazine and clopenthixol, on the drug efflux of
mouse T-lymphoma cells expressing the ABCB1 transporter
(P-glycoprotein). It has been found that the stereoselectivity
does not have any effect on the inhibition of the efflux pump
activity of enantiomers (6). Similar findings have been
obtained after the chemical resolution of N-hydroxyalkyl-2-
aminophenothiazines, namely the enantiomers were shown
to have similar activity on the inhibition of the ABCB1
transporter of rat hepatocytes (7). 
The main question of this work was whether the chirality of
resolved phenothiazine derivatives can play a role in the
inhibition of the AcrAB-TolC efflux pump system of a wild-type
Gram-negative bacterium of pathogenic interest. For this reason
we used the AcrAB-TolC system of E. coli K-12 AG100 (wild-
type, genetically defined strain) and racemic phenothiazines and
their (+) –and (–)– enantiomers. Representative efflux pumps
such as the E. coli AcrAB-TolC have been used to screen and
characterize possible EPIs. An automated real-time screening
method has been developed by Viveiros et al., which can be used
routinely for the screening of EPIs (8) under physiologically
relevant conditions (i.e. pH). This screening method was used to
elucidate the activity of the different phenothiazine enantiomers
on the bacterial AcrAB-TolC system.
Materials and Methods
Bacterial strains. Wild-type E. coli K-12 AG100 strain [argE3 thi-
1 rpsL xyl mtl Δ(gal-uvrB) supE44] expressing the AcrAB-TolC
efflux pump at its basal level. The strain was kindly provided by
Hiroshi Nikaido (Department of Molecular and Cell Biology and
Chemistry, University of California, Berkeley, CA, USA). 
Materials. Mueller Hinton (MH) powder (Sigma-Aldrich, St. Louis,
MO, USA) was used for the preparation of MH broth. E. coli
cultures were grown on solid (1.5% agar) for isolation or liquid
Luria Bertani (LB) medium purchased from Difco, Detroit, MI,
USA. Ethidium bromide (EB) was purchased from Sigma-Aldrich.
Compounds (EPIs). The synthesis and chemical resolution of the
phenothiazines derivatives were described previously (7); the
structures are depicted in Table I.
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-morpholin-4-yl-
10H-phenothiazin-10-yl)butan-2-ol (rac-3h)
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-[2-(4-methylpiperazin-
1-yl)-10H-phenothiazin-10-yl]butan-2-ol (rac-3i)
1-(2-Chloro-10H-phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butan-2-ol (rac-5).
Minimum inhibitory concentration (MIC) determination. The MIC of
phenothiazine derivatives was tested according to Clinical and
Laboratory Standard Institute (CLSI) guidelines for dilution anti-
microbial susceptibility tests (9). All assays were repeated three times.
Real-time EB accumulation assay. The activity of compounds on the
real-time accumulation of EB was assessed by the automated EB
method (8, 10), using a Rotor-Gene 3000™ thermocycler with real-
time analysis software (Corbett Research; Sydney, Australia). Briefly,
an aliquot of an overnight culture of the strain in LB medium was
transferred to fresh LB medium and incubated until it reached an
optical density (OD) of 0.6 at 600 nm, washed with phosphate
buffered saline (PBS pH 7.4) and centrifuged at 13,000 × g for 3
minutes. The pellets were re-suspended in PBS (pH 7.4) and the OD
adjusted to 0.6 at 600 nm. Aliquots of 45 μl of the cell suspension
were distributed to 0.2 ml tubes. The compounds were added
individually at the concentration of 100 μM in 5 μl volumes of their
stock solutions and, finally, 45 μl of EB were added to yield a final
concentration of 1 mg/l in PBS with and without glucose 0.4%. The
tubes were placed into the Rotor Gene 3000™ thermocycler that
monitors the excitation wavelength (535 nm) and the emission
wavelength (585 nm). The fluorescence associated with retained EB
was monitored on a real-time basis.
If an agent is to be studied for activity against an efflux pump system
it must be applied at concentrations that do not affect the replication or
viability of the cell (8). Because the MICs of the phenothiazine
derivatives exceeded the concentration of 400 μM, the sub-inhibitory
concentrations for the accumulation assays were employed at 100 μM.
in vivo 28: 1071-1076 (2014)
1072
Table I. The structure and the chemical formula of the phenothiazines
used in the study.
From the real-time data, the activity of the compound, namely the
relative fluorescence index (RFI) of the last time point (minute 60) of
the EB accumulation assay, was calculated according to the formula:
RFtreated–RFuntreated
RFI=
RFuntreated
where RFtreated is the relative fluorescence (RF) at the last time point
of EB retention curve in the presence of an inhibitor; and RFuntreated
is the relative fluorescence at the last time point of the EB retention
curve of the untreated control having the solvent control (DMSO)
(11). The greater the difference between RFtreated and RFuntreated the
greater the degree of the EB accumulated and, therefore, the greater
the degree of inhibition of the efflux pump system of the bacterium
by the agent. The experiments were repeated three times and the
RFI values presented are the average of three independent assays.
Statistical analysis. Statistical analyses were conducted using a one-
way analysis of variance (ANOVA) complemented by the
Bonferroni post-test for multiple comparisons. The level of
significance was p<0.05. The analyses were performed using the
GraphPad Prism version 5.00 for Windows, GraphPad Software
(San Diego, CA, USA, www.graphpad.com). 
Results 
The phenothiazine derivatives had no prominent antibacterial
effect on E. coli AG100 expressing the AcrAB-TolC efflux
pump, the MICs were above 400 μM and the DMSO as
solvent had no antibacterial effect at the concentration
applied in the assays (5 % v/v). There was no difference
between the (+)- and (–)-enantiomers and the racemic
compound in their antibacterial effect; all of them had an
MIC above the concentration of 400 μM.
After determining the MICs, the RFI was calculated for
each derivative. As shown in Figure 1, the most active EPIs
for the modulation of the AcrAB-TolC pump were
compounds rac-3i, (+)-3i, and (–)-3i. 
The difference between the enantiomers in terms of RFI
was evaluated by one-way analysis of variance (ANOVA)
with Bonferroni post-test for comparing all pairs of results
by using the GraphPad Prism software. A 95% confidence
interval has been chosen for the analysis and the means of
the triplicate assays were compared. Comparison of RFI
values for the enantiomeric derivatives revealed that their
activities were comparable to that of the racemic derivatives.
The statistical analysis confirmed that the mean of the RFI
values for the racemic and enantiomeric derivatives were not
significantly different (p>0.05) (Table II).
Since the racemic phenothiazines and their corresponding
enantiomers exhibited equivalent efflux pump-inhibiting
activity on the AcrAB-TolC efflux pump system of E. coli
AG100, the racemic phenothiazines and their corresponding
enantiomers have been evaluated as identical compounds in
the following analysis concerning the energy supply of the
AcrAB-TolC efflux pump system.
Because RND efflux pumps obtain their energy for activity
from the proton motive force (PMF) and the PMF results from
metabolic activity of the cell, the EPI effect of phenothiazines
on the AcrAB-TolC efflux pump system was assessed in the
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Figure 1. The activity of the most effective N-hydroxyalkyl-2-aminophenothiazine derivatives (rac-3i, (+)-3i, (–)-3i) at 100 μM on the accumulation of EB
by E. coli AG100, in the presence and absence of glucose 0.4%, after 30 min. Legend: — solvent control; l rac-3i without glucose; s (+)-3i without
glucose; n (–)-3i without glucose; --- solvent control with glucose; l rac-3i with glucose, s (+)-3i with glucose, n (–)-3i with glucose.
presence and absence of 0.4% of glucose at pH 7.4. As
expected, the RFI values of the N-hydroxyalkyl-2-
aminophenothiazines are significantly lower (p<0.05) if glucose
is present in the system, thereby indicating that glucose plays
an important role in reducing the amount of EB accumulated
by E. coli AG100 in the presence of N-hydroxyalkyl-2-
aminophenothiazines at pH 7.4 (example: N-hydroxyalkyl-2-
aminophenothiazine rac-3i, Figure 2). The phenothiazines rac-
3h and rac-5 showed significantly less activity in the presence
of the indirect energy source glucose (Figure 2).
Discussion
RND proteins are part of tripartite pumps and they mediate
transport across the inner and outer bacterial membrane. The
conformational changes and the dynamic transition of the
different configurations of the AcrB protein have to be
elucidated in order to design effective EPIs (12). The
discovery of the inhibitor-bound structures of AcrB described
by Nakashima et al. in 2013 contributed enormously to the
EPI-discovery strategies related to the RND transporters (13).
From the observations presented, it can be concluded that the
chirality of resolved N-hydroxyalkyl-2-aminophenothiazines
does not influence the EPI activity of the derivatives on the
bacterial AcrAB-TolC efflux pump system of E. coli AG100. It
can be suggested that there is no direct interaction between the
phenothiazine derivatives and the AcrB protein. Furthermore,
they may influence the expression of genes regulating the
AcrAB-TolC system (14). It was previously shown that
promethazine might form a complex with two guanine–cytosine
(G–C) rich regions of DNA (15). In addition, phenothiazine
derivatives can cause unspecific reactions with membrane lipids
because of the high degree of their lipophilicity (16).
However, if glucose is present in the system, the activity
of the N-hydroxyalkyl-2-aminophenothiazines will be
diminished demonstrating the role of energy supply on the
activity of the bacterial AcrAB-TolC efflux pump system. 
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Table II. Statistical analyses of the relative final fluorescence index (RFI) of racemic phenothiazines (rac-3h, rac-3i, rac-5) and their (+)- and (–)-
enantiomers using a one-way analysis of variance (ANOVA) complemented by the Bonferroni post-test for multiple comparisons. R2 is the fraction
of the overall variance attributable to differences among the group means (R2=0.279), the F ratio is the ratio of two mean square values (F=0.8705).
ANOVA Table Sum of squares Degrees of freedom Mean square
Treatment (between columns) 1.179 8 0.1474
Residual (within columns) 3.047 18 0.1693
Total 4.226 26
Bonferroni’s multiple comparison test Mean difference Significance (p<0.05) 95% Confidence interval of difference
Groups Lower bound Upper bound
rac-3h vs. (+)-3h 0.0205 No –0.8952 0.9362
rac-3h vs. (–)-3h 0.081 No –0.8347 0.9967
(+)-3h vs. (–)-3h 0.0605 No –0.9426 1.067
rac-3i vs. (+)-3i 0.01033 No –0.9054 0.926
rac-3i vs. (–)-3i –0.3723 No –1.191 0.4467
(+)-3i vs. (–)-3i –0.3827 No –1.298 0.533
rac-5 vs. (+)-5 0.287 No –0.8604 1.255
rac-5 vs. (–)-5 0.0995 No –0.9036 1.103
(+)-5 vs. (–)-5 –0.1875 No –1.191 0.8156
Figure 2. The effect of glucose on RFI index in the presence of N-
hydroxyalkyl-2-aminophenothiazines: the activity of racemic
phenothiazines (rac-3h, rac-3i, rac-5) and their enantiomers at 100 μM
on the accumulation of EB by E. coli AG100 in the presence and
absence of glucose 0.4%. Legend: w, with glucose 0.4%; w/o, without
glucose 0.4%; *the correlation is significant: p<0.05; **the correlation
is very significant: p<0.01.
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